Airtasker Limited (ASX:ART) Reports Strong Half-Year Financial Performance
Airtasker Limited (ASX:ART) reports a 10% revenue increase and significant loss reduction in its half-year financial results.
Category: Information Technology
Camplify Holdings Ltd (ASX:CHL) Releases H1FY25 Interim Results
Camplify Holdings Ltd (ASX:CHL) reports a 17.8% revenue decrease in H1FY25, highlighting strategic initiatives toward profitability.
Dicker Data Limited (ASX:DDR) Reports FY2024 Financial Results
Dicker Data Limited (ASX:DDR) reports a 0.7% revenue increase for FY2024, with gross sales up 2.8% and dividends paid totaling 44 cents per share.
Raiz Invest Limited (ASX:RZI) Reports 14% Revenue Growth and Exits Southeast Asia
Raiz Invest (ASX:RZI) reports a 14% revenue increase for half-year 1H FY25, highlighting strategic growth and partnerships.
Swoop Holdings Limited (ASX:SWP) Reports 1H FY25 Financial Results
Swoop Holdings Limited (ASX:SWP) reports a 5% revenue increase and significant subscriber growth in 1H FY25, highlighting strong operational performance.
BlueBet Holdings Ltd (ASX:BBT) Offers $340-$360M to Acquire PointsBet
BlueBet Holdings Ltd (ASX:BBT) offers $340-$360M to acquire PointsBet, aiming to realise $40M in annual synergies.
WiseTech Global Limited (ASX:WTC) Announces New Board Appointments
WiseTech Global (ASX:WTC) announces new board members and updates on governance and succession planning.
Light & Wonder, Inc. (ASX:LNW) Announces 2024 Performance and Strategic Acquisitions
Light & Wonder (ASX:LNW) reports 10% revenue growth in 2024, initiates significant share repurchases, and announces the acquisition of Grover Charitable Gaming.
EML Payments Limited (ASX:EML) Announces 1HFY25 Results
EML Payments Limited (ASX:EML) reports a 15% revenue increase and $9.5m net profit in 1HFY25, highlighting strong growth and reaffirmed FY25 guidance.
Archer Materials Limited (ASX:AXE) Enhances Biochip Feasibility and Advances Development Roadmap
Archer Materials Limited (ASX:AXE) improves Biochip’s potassium detection accuracy, advances to human blood testing, and plans regulatory engagements.